Open AccessApplication of contrast-enhanced ultrasound in the diagnosis of post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation
Author(s) -
Weinan Chen,
Jianchun Li,
Xiaodong Fan,
Yanming Zhang,
Li Wang,
Yang Liu,
Ailin Cui,
Ligang Wang
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024047
Subject(s) - medicine , hematopoietic stem cell transplantation , radiology , contrast enhanced ultrasound , biopsy , cyclophosphamide , transplantation , post transplant lymphoproliferative disorder , lymphoma , chemotherapy , ultrasound , pathology , rituximab
Abstract Introduction: Post-transplant lymphoproliferative disease (PTLD) is a series of proliferative diseases of the lymphatic system. Among patients receiving hematopoietic stem cell transplantation (HSCT), PTLD is a prevalent complication that severely affects rates of survival. Ultrasound plays an essential role in the early diagnosis of PTLD. Contrast-enhanced ultrasonography (CEUS) and CEUS-guided biopsy are critical procedures for tumor diagnosis. Patient concerns: Herein, we report the case of a 40-year-old male patient with acute lymphoblastic leukemia who received HSCT more than 1 year ago. Sonography revealed a small hypoechoic nodule in the liver four months after HSCT. Eight months after HSCT, larger and more nodules were observed via ultrasound; CT was used to identify the lesions. Diagnoses: CEUS and CEUS-guided biopsy were performed, and the pathological diagnosis was PTLD. Interventions: The final clinical diagnosis was PTLD, and cyclophosphamide, epirubicin, and dexamethasone were administered as chemotherapy. Outcomes: The patient was discharged after his condition improved. Conclusion: Ultrasound can be used to effectively detect lesions of PTLD early after HSCT. Furthermore, CEUS and CEUS-guided biopsy were effective for early confirmatory diagnoses of PTLD after HSCT.